Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Tax Provisions (2020 - 2025)

Collegium Pharmaceutical (COLL) has 6 years of Tax Provisions data on record, last reported at $11.9 million in Q3 2025.

  • For Q3 2025, Tax Provisions rose 91.02% year-over-year to $11.9 million; the TTM value through Sep 2025 reached $32.4 million, up 12.98%, while the annual FY2024 figure was $4.7 million, N/A changed from the prior year.
  • Tax Provisions reached $11.9 million in Q3 2025 per COLL's latest filing, up from $4.7 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $11.9 million in Q3 2025 and bottomed at -$61.9 million in Q2 2021.
  • Average Tax Provisions over 5 years is -$2.2 million, with a median of $975000.0 recorded in 2022.
  • Peak YoY movement for Tax Provisions: plummeted 25243.09% in 2021, then soared 735.79% in 2023.
  • A 5-year view of Tax Provisions shows it stood at -$13.8 million in 2021, then soared by 95.72% to -$592000.0 in 2022, then surged by 1476.52% to $8.1 million in 2023, then tumbled by 41.92% to $4.7 million in 2024, then surged by 152.04% to $11.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $11.9 million in Q3 2025, $4.7 million in Q4 2024, and $6.2 million in Q3 2024.